cyrilzakka/clinical-trials huggingface dataset:
Effectiveness of Ophthalmic Antiseptic Preparations

The aim of this clinical trial is to evaluate the effectiveness of two topical antiseptics, povidone-iodine (PVI) and chlorhexidine (CHX), in reducing conjunctival bacterial flora.

70 patients undergoing cataract surgery were enrolled and randomly divided in two arms: 35 patients used PVI 0.66% 4 times daily starting 3 days before surgery; 35 patients used CHX 0.02% with the same posology. The contralateral eye was considered as control. Conjunctival swabs were collected in both eyes at the baseline (T0) and after three days of treatment (T1) all before cataract surgery. Conjunctival bacterial load has been evaluated through a molecular based method at T0 and T1 and compared to the control eye.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing cataract surgery
* 18 years of age or older

Exclusion Criteria:

* Reported allergy or hypersensitivity to iodine or chlorhexidine
* Active ocular infection
* Contraindication to surgery
* Pregnant women
* Patients residing in nursing homes or prison
* Patients who used antibiotic, antiviral or antifungal eye drops in the week preceding the intervention
Evaluating the Response to Neoadjuvant Chemotherapy With Circulating Tumor DNA in Pancreatic Cancer

For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.

Cancer DNA in the blood stream is called circulating tumor DNA or ctDNA. The presence or absence of pancreatic cancer ctDNA in the blood stream may help clinicians to better understand pancreatic cancer behavior in response to specific treatments, like chemotherapy and surgery. Understanding how treatment alters the ctDNA can help future patients diagnosed with pancreatic cancer. The presence or absence of ctDNA or the clearance of ctDNA after treatment may help to guide further treatment decisions for cancer patients after surgery.

Eligibility Criteria:
Inclusion Criteria:

* Biopsy or cytology proven adenocarcinoma of the pancreas
* No clinical evidence of metastatic disease on imaging
* Age 18 or older
* Receiving chemotherapy for non-metastatic pancreatic cancer

Exclusion Criteria:

* Biopsy proven metastatic disease
Strategies to Maintain Cardiac Risk Control After Discharge From Cardiovascular Risk Reduction Clinic

The purpose of this study is to determine whether a combined behavioral and pharmacological intervention provided by a multidisciplinary team will further reduce LDL-C, smoking, BP and Hb-A1C in diabetic patients with A1c between 7% and 9% when compared to usual care.


Eligibility Criteria:
Inclusion Criteria:

* Previous enrollment in Cardiovascular Risk Reduction Clinic (CRRC)
* Eligible for CRRC discharge:

  1. For DM patients:

     * HbA1c \< 7.0 %,
     * BP \< 130/85 mm Hg , and
     * LDL \< 100 mg/dl;
  2. For Non-DM patients:

     * BP \< 140/90 mm Hg, and
     * LDL \< 100 mg/dl;
* Able and willing to sign informed consent.

Exclusion Criteria:

* Presence of conditions that might limit long-term compliance (eg, dementia, acute psychiatric decompensation within the previous 6 months, unstable psychiatric disorder);
* Metastatic disease or terminal illness
Airway Scope and Macintosh Laryngoscope for Tracheal Intubation in Patients Lying on the Ground

Pre-hospital intubation is often required in sub-optimal conditions, such as in patients lying on the ground. Direct laryngoscopy and intubation of a patient lying supine on the ground is difficult because the intubator's head is far above the head of the patient. It is thus tricky to align the intubator's visual axis with the patient's tracheal axis. The Airway Scope is a new laryngoscope designed to facilitate intubation without requiring alignment of the oral, pharyngeal, and tracheal axes. We thus tested the hypothesis that the intubation with the Airway Scope is faster than the Macintosh laryngoscope in subjects lying on the ground.

Adult surgical patients were enrolled. Following anesthesia induction and muscle relaxation, direct laryngoscopy was performed as usual and airway characteristics noted. Patients were randomly assigned to tracheal intubation by either the Airway Scope (n=50) or the Macintosh laryngoscope (n=50). Intubation was performed from a table positioned at the height as the operating table, thus simulating intubating on the ground. Overall intubation success rate, time required for intubation, the number of attempts required for successful intubation, and airway complications related to intubation were recorded.

Eligibility Criteria:
Inclusion Criteria:

* Patients scheduled for various surgeries requiring tracheal intubation as part of anesthesia and designated as American Society of Anesthesiologists (ASA) physical status I, II, or III.

Exclusion Criteria:

* Patients with an increased risk of pulmonary aspiration, cervical spine pathology, anticipated airway difficulties (i.e., Mallampati grade IV or thyromental distance \<6 cm), and American Society of Anesthesiologists physical status \>III.
Personalized FET in RIF Patients With Displaced Dating

The endometrium becomes receptive as a result of a series of timed hormonal events during the menstrual cycle. The exposure of the endometrium to progesterone after ovulation initiates morphological and functional alterations that result in the change from a pre-receptive to a receptive endometrium. The morphological changes observed on histology for each specific day after ovulation were described by Noyes and his colleagues in 1950. An endometrial biopsy that shows a difference of more than 2 days between the histologic dating and actual day after ovulation is considered to be "out of phase" However, the clinical application of the Noyes criterion is relatively limited. We have verified the Noyes criterion in natural cycle in previous study which conducting endometrial biopsies respectively on day 3, 5, 7, 9 and 11 of post-ovulation (PO+3/5/7/9/11)(unpublished data).

The clinical value of the endometrial histological dating in RIF patients in natural cycle is still to be answered. In this study, we tried to investigate the clinical effects of pFET in unexplained RIF patients according to the use of classic histologic endometrial dating to estimate the timing of the window of implantation and to adjust embryo transfer time in natural cycle.


Eligibility Criteria:
Inclusion Criteria:

1. RIF patients (RIF is defined as the absence of a gestational sac on ultrasound at 5 or more weeks after 3 embryo transfers with high quality embryos or after the transfer of ≥10 embryos in multiple transfers);
2. Out of phase dating patients;
3. FET in natural cycle;
4. Single blastocysts embryo transfer;

Exclusion Criteria:

1. uterine abnormalities (double uterus, bicornuate uterus, unicornuate uterus and uterine mediastinum), intrauterine adhesions, endometriosis,adenomyosis, hydrosalpinx, and uterine fibroids (submucosal fibroids, non-mucosal fibroids\> 4 cm and/or endometrial pressure);
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on the maintenance of remission and duration of response in adults with primary MCD or primary FSGS who previously responded to steroid therapy.


Eligibility Criteria:
Inclusion Criteria:

1. Is ≥ 18 years of age at the time of informed consent;
2. Kidney biopsy-proven diagnosis of primary MCD or primary FSGS within the past 10 years. Subjects with kidney biopsy-proven diagnosis of primary MCD or primary FSGS greater than 10 years and less than 20 years prior to Screening who meet all other eligibility criteria may be enrolled after discussion with the Medical Monitor
3. History of steroid-sensitive MCD or FSGS, defined as having achieved complete remission of proteinuria (reduction of proteinuria to \<0.5 g/g UPCR) after use of corticosteroids;
4. Has experienced meaningful proteinuria in the last 2 years prior to Screening, defined as UPCR \>2.0 g/g, after attempted or completed tapering of steroids and/or CNIs that occurs within 6 months of the attempt or completion of tapering;
5. Currently on prednisone regimen at time of Screening and anticipated to be tapered to a stable dose of prednisone of no more than 20 mg/day for at least 14 days prior to Day 1
6. Has systolic blood pressure (BP) \<160 mmHg or diastolic BP \<100 mmHg after 5 minutes of rest at Screening;
7. Is willing and able to provide written informed consent prior to Screening;
8. Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit) or postmenopausal, defined as spontaneous amenorrhea for at least 2 years, with follicle-stimulating hormone in the postmenopausal range at Screening, based on the central laboratory's ranges;
9. Female subjects of childbearing potential (ie, ovulating, premenopausal, or not surgically sterile) and all male subjects must use a medically accepted, highly effective contraceptive regimen during their participation in the study and for 125 days (4 months) after the last administration of study drug.
10. Male subjects must agree to abstain from sperm donation through 125 days (4 months) after administration of the last dose of study drug.

Exclusion Criteria:

1. Has an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2 at Screening utilizing the Chronic Kidney DiseaseEpidemiology Collaboration formula confirmed by the central laboratory;
2. Has an absolute neutrophil count \<1.5 x 10/L;
3. Has a white blood cell count \<3.0 x 10/L;
4. Has secondary causes of MCD or FSGS (eg, malignancy, hepatitis B or C, human immunodeficiency virus \[HIV\], systemic lupus erythematosus \[SLE\], or other autoimmune diseases \[eg, thyroiditis\], drug-induced);
5. Has a diagnosis or history of SLE (including non renal disease);
6. Has type 1 or 2 diabetes mellitus;
7. Has an acute, chronic, or latent infection, including tuberculosis, hepatitis, HIV, or chronic urinary tract infection.
Effect of Bariatric Surgery on Cardiac Function in Patients with Hypertension

The purpose of this study is to investigate the effect of bariatric surgery on cardiac function assessed by echocardiography in patients with hypertension.

Obesity is the most common chronic metabolic disease worldwide, causing the increasing burden of cardiovascular risk factors such as hypertension, and affecting cardiac structure and function in the long term. Nowadays, bariatric surgery is regarded as the most effective approach for weight loss, and the only approach for reducing obesity-related cardiovascular events. However, the effect of different bariatric surgeries such as laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB) on cardiac function in patients with hypertension is still unclear. Therefore, the aim of this study was to evaluate the benefit of different bariatric surgeries on cardiac structure and function echocardiography in patients with hypertension.

Eligibility Criteria:
Inclusion Criteria:

* 18-70 years old
* BMI\>24kg/m2
* Bariatric surgery patients of Beijing Friendship Hospital
* History of hypertension and treated with ≥2 antihypertensive drugs for more than 4 weeks
* No major barriers to provide written consent

Exclusion Criteria:

* Secondary hypertension, except because of sleep apnea
* cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months
* Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases)
* Unable to understand or comply with the study procedures
Music and Essential Oil in Agitation

The study aims to assess the effect of using music and essential oil on agitation in mechanically ventilated patients. Listening to classical relaxation music, and inhalation to bergamot oil will be used in this study.

Agitation in critically ill patients is a phenomenon that can compromise patient safety and assistance during intensive care unit (ICU) hospitalizations. This trial will be conducted in five general intensive care unit. One hundred and twenty patients will be enrolled in this study divided into three equal groups (40 patients in each group). Group A is the control group. Group B is music group. Group C is essential oil group. Agitated mechanically ventilated patients will be randomly assigned to one of the three groups. Each group will be subjected to its specific intervention and they will be monitored for seven days. Agitation score and frequency outcome will be assessed at the end of the study.

Eligibility Criteria:
Inclusion Criteria:

* Agitation with RASS score +2 or more
* Mechanical ventilation
* Patients with GCS 13-15

Exclusion Criteria:

* Psychiatric illness
* Cognitive disorders
* Neurological disorder
* Hearing deficit
* Smelling deficit
* Respiratory asthma
* Allergic rhinitis
Color Doppler U/S vs MSCT Venography in May-Thurner Syndrome

May-Thurner syndrome is the result of compression of the left common iliac vein between the right common iliac artery and overlying vertebrae.

In This Study , We will detect the role of color doppler US in the diagnosis of May-Thurner Syndrome in comparison to Direct CT Venography

May-Thurner syndrome (MTS) is a venous compression syndrome in which the left common iliac vein is compressed between the lower lumbar spine and the right common iliac artery. While asymptomatic compression is very common, the process can lead to morbidity in selected individuals, most commonly deep venous thrombosis (DVT) and the sequelae thereof. Radiologists must recognize the diagnosis because of the unique management, which differs from DVT without iliac vein compression.

The most common clinical presentation is unilateral leg swelling due to acute DVT. It can also present as chronic venous insufficiency or chronic thrombosis with symptoms of venous hypertension and venous stasis namely claudication, pain, swelling, varicose veins and / or ulceration.

Conventional invasive catheter venography remains the gold standard for diagnosis,but the decision to undertake invasive venography should be made only after reviewing all available clinical data and alternative, less invasive imaging options have been exhausted.

When visualization of the common iliac veins is possible, MTS may be diagnosed with transabdominal color Doppler U/S.

MDCT with IV contrast is a fast, widely available examination for the diagnosis of MTS and accompanying complications .

Magnetic resonance imaging (MRI) with MR venography is an attractive modality for the diagnosis, However, MRI is expensive, time consuming, has more limited availability than computed tomography (CT) and ultrasound, and may be impossible in select patients.

Eligibility Criteria:
Inclusion Criteria:

* advanced chronic venous insufficiency submitted to clinical treatment for at least 1 year with no response.
* Subject must be \> 18 and \< 80 years of age.
* informed consent document before the planned procedure.
* On duplex ultrasound: patent common femoral vein, and patent deep femoral vein, and/or femoral vein of the study leg.

Exclusion Criteria:

* Previous venous stent implantation involving the study leg or inferior vena cava
* Previous venovenous bypass surgery involving the study leg
* Known reaction or sensitivity to iodinated contrast that cannot be managed with premedication.
* Subjects who are pregnant (women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment).
* Acute deep venous thrombosis involving either leg.
* Known history of chronic total occlusion of the common femoral vein of the study leg.
* Venous compression caused by tumor encasement.
* Venous outflow obstruction caused by tumor thrombus.
* Elevated baseline blood creatinine (value greater than the upper limit of the normal range).
Comparison of Different Video Laryngoscopes in a Manikin With Immobilized Cervical Spine

To determine whether different video laryngoscopes facilitate intubation in an manikin with immobilized cervical spine compared with standard laryngoscopy.


Eligibility Criteria:
Inclusion Criteria:

* anaesthesiologist
* experienced in tracheal intubation

Exclusion Criteria:

* missing experience in tracheal intubation
* missing informed consent
Ceramide Containing Multivesicular Emulsion Application . . .

We believe that using a ceramide based foot cream two times a day for two weeks will prevent water loss and overall foot dryness in patients with non-insulin dependent diabetes.


Eligibility Criteria:
Inclusion Criteria:

* \>18 years of age
* non insulin-dependent diabetes
* moderate to severe xerosis of both feet \[a score of at least 4 on a scale of 0 (normal) to 8 (deep fissuring)\]
* capable of understanding and signing consent form

Exclusion Criteria:

* history of ichthyosis vulgaris
* known hypersensitivity to the topical product used in the study
* previous use of high potency steroids (class I and II) in past 2 week
* presence of acute skin disease or infection, such as vasculitis or cellulitis
* presence of foot ulcer
* evidence of gangrene
Pharmaceutical Care Program for Type 2 Diabetes Mellitus

Evaluation of Pharmaceutical Care Program for Type 2 diabetes mellitus in Dhule

Objectives:-

1. To evaluate Pharmaceutical care program in Type2 diabetics.
2. To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.
3. To study the prevalence of Type2 diabetics cases in Dhule.
4. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.
5. To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.
6. To study the impacts of Pharmaceutical care program on glycemic control in patients with Type-2 Diabetes Mellitus.
7. To study the Drug utilization pattern in Type-2 Diabetes Mellitus in civil hospital Dhule.
8. To compare the efficiency of Pharmaceutical care program and drug in patients with Type-2 Diabetes Mellitus.
9. To study the Pharmaco-economic evaluation in Type-2 Diabetes Mellitus patient's.
10. To increase the patient compliance and positive attitude of patients towards the diabetes disease by counseling.

To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.

To study the prevalence of Type2 diabetics cases in Dhule. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.

To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.

Eligibility Criteria:
Inclusion Criteria:Inclusion Criteria:

* Patients with type 2 diabetes mellitus of either
* Patients with HbA1c more than 7% and
* Patients with blood sugar level more than 140 mg / dl

Exclusion Criteria:

* Patient with end stage kidney disease.
* Patient with heart failure.
* Patient with chronic Diabetes problem and orthopedic problem
Mobile Coach for Parents of Children and Adolescents With Chronic Pain

Chronic pain is estimated to affect 20% to 35% of children and adolescents around the world, and is associated with increased risk of anxiety and depression among children and adolescents, as well as coping challenges, anxiety, depression, and anger in their parents. For parents, learning to manage stress is critical, as parents play a significant role in a child's experience of pain. Parental behaviors such as over-involvement, solicitousness and rejection are associated with decreased functioning, including higher school absenteeism in children and teens. A number of interventions demonstrate that teaching skills to parents can have a direct and positive impact on the health of children and adolescents with chronic pain. The investigators propose to create and test the BodiMojo Parent Buddy which will provide parents with real-time, tailored and adaptive coping and stress management support and will provide a curriculum of skills for responding to a child in pain in order to promote child functioning.

Thirty parents of children ages 8-18 who have been diagnosed with a non-cancer chronic pain condition will participate in this user-testing study. Parents will complete a brief set of questionnaires before and after the intervention, and will be instructed to open and use the app each day for 30 days. Participants will complete audio mindfulness exercises, watch brief video clips, and read psychoeducational information about pain, coping, and communication skills. Post-intervention questionnaires will also include an acceptance test to assess participants' opinions about the helpfulness and usability of the app. Parent participation is expected to take around 3.5 hours total over the 30 day study period.


Eligibility Criteria:
Inclusion Criteria:

* Parents who self-report parenting a child or adolescent ages 8-18 with non-cancer chronic pain.
* Daily use of a smartphone (iOS, Android, or Windows) or tablet.
* Ability to speak and understand English.

Exclusion Criteria:

* Inability to provide consent
* Inability to speak and understand English
Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV Infection

RATIONALE: Collecting the T cells from a donor and transplanting them into a patient may be effective treatment for immunodeficiency syndrome and CMV infection.

PURPOSE: This clinical trial is studying the emergency use of adoptive immunotherapy with CMV-specific T cells after donor bone marrow transplant of an infant with immunodeficiency syndrome and CMV infection.

OBJECTIVES:

* To determine if adoptive immunotherapy with donor-derived CD4+ and CD8+ CMV- specific cytotoxic lymphocyte cell lines can augment T-cell immunity and treat CMV infection post transplant in a patient with severe combined immunodeficiency syndrome.

OUTLINE: The patient will undergo HLA-matched unrelated donor bone marrow transplantation from a CMV-seropositive donor after undergoing conditioning with 200cGy total-body irradiation per protocol FHCRC Protocol 1227.

CD8-positive and CD4-positive CMV-specific T cells are collected from the donor and used to generate T-cell lines.

If the patient has progressive or persistent CMV infection, then she will receive donor T cells IV over 30 minutes. Infusions may be repeated after at least 14 days if the previous infusion was well tolerated and if the CMV infection is persistent or increasing.

The patient undergoes blood sample collection at baseline and 7 days after T-cell infusion to assess CMV-specific T-cell response.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Adenosine deaminase-deficient severe combined immunodeficiency syndrome (ADA-SCIDs)
* CMV interstitial pneumonia based on the constellation of clinical and radiological findings

PATIENT CHARACTERISTICS:

* Female
* Oxygen desaturation (pulse oximetry 85% on room air)
* Abnormal chest radiograph
* No CMV retinitis

PRIOR CONCURRENT THERAPY:

* Prior ganciclovir and foscarnet sodium